CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Activities
Net income (loss)	$ (5,810)	$ (21,430)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	750	538
Bad debt expense	161	30
Amortization of debt issuance costs	202	195
Provision for obsolete inventory	70
Non-cash lease expense	80	69
Shares issued in settlement of litigation		1,199
Share-based compensation expense	1,763	2,170
(Gain) loss from change in fair value of warrant liability		1,618
Loss from change in fair value of earnout liability	12,089	25,410
Deferred income taxes		103
Changes in operating assets and liabilities:
Accounts receivable	(1,329)	(728)
Inventory	75	1,560
Other current assets	619	1,238
Accounts payable	(109)	857
Deferred revenue	(22)	205
Accrued expenses	(1,094)	(22)
Operating lease liabilities	(73)	(20)
Net cash provided by operating activities	7,372	12,992
Investing Activities
Purchases of property and equipment	(704)	(62)
Purchases of capitalized software	(350)	(318)
Acquisitions, net of cash acquired	(11,122)
Net cash used in investing activities	(12,176)	(380)
Financing Activities
Repurchases of common stock	(4,088)
Principal repayments on term loan	(1,562)	(1,562)
Proceeds from exercise of stock options	324	420
Distributions	(83)	(3,093)
Net cash used in financing activities	(5,409)	(4,235)
Effect of exchange rate changes on cash and cash equivalents	(2)
Net increase (decrease) in cash and cash equivalents	(10,215)	8,377
Cash and cash equivalents at beginning of period	89,002	79,231
Cash and cash equivalents at end of period	78,787	87,608
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	2,230	2,230
Cash paid for income taxes	2	2,232
Non-cash investing and financing activities
Capital expenditures and capitalized software included in accounts payable	85	$ 94
Shares issued to acquire Simpatra	$ 1,574